Strides Pharma Science Limited has informed the Exchange regarding a press release dated April 30, 2025, titled "Strides Strengthens Anti-Inflammatory Portfolio with USFDA Approval for Celecoxib Capsules, 100 mg, 200 mg, and 400 mg".
Strides Pharma Science Limited has informed the Exchange regarding a press release dated April 30, 2025, titled "Strides Strengthens Anti-Inflammatory Portfolio with USFDA Approval for Celecoxib Capsules, 100 mg, 200 mg, and 400 mg".